enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Growth Opportunities F. Forbion Purchases 2,750 Shares

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion acquired 2,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 27th. The stock was acquired at an average price of $7.17 per share, with a total value of $19,717.50. Following the completion of the transaction, the insider now directly owns 2,002,750 shares in the company, valued at $14,359,717.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

enGene Price Performance

Shares of ENGN opened at $9.02 on Friday. The company has a 50 day moving average of $6.71 and a 200-day moving average of $9.78. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $398.38 million, a P/E ratio of -5.24 and a beta of -0.69. enGene Holdings Inc. has a twelve month low of $4.42 and a twelve month high of $43.00.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, equities research analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on ENGN shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene currently has an average rating of “Buy” and an average target price of $33.67.

Institutional Trading of enGene

Institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new position in enGene in the first quarter valued at approximately $17,095,000. SR One Capital Management LP acquired a new stake in shares of enGene in the 2nd quarter valued at approximately $4,715,000. Logos Global Management LP grew its stake in shares of enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares in the last quarter. Finally, Altitude Crest Partners Inc. acquired a new position in enGene during the first quarter worth $2,039,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.